| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Bruker Corporation$55.82
-0.05 (-0.1%)
F 17Pipeline Score Tools & Services · Commercial
Market Cap
6.96 B
EPS
-0.24
P/E Ratio
-
Value Trade
268.61 M
SEC Financials
Q1 2026Dilution Risk
Revenue
823.40 M
R&D Expenses
101.30 M
Operating CF
71.20 M
Total Assets
6.13 B
Total Liabilities
6.13 B
Equity
2.47 B
D/E Ratio
12,345
4.08 %
Week
12.62 %
1 Month
19.26 %
3 Month
3.37 %
6 Month
-34.67 %
5 Year
123.22 %
All Time
Cash Data
Cash Position
137.60 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
353.88 K
52 Week Range
28.53 - 56.22
% held by Insiders
27 %
% held by Institutions
91.38 %
Enterprise Value
8.55 B
Total Shares
152.12 M
Short %
12.37 %
Float Shares
111.20 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F17
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 16%
Small Cap (rank 761 of 905)
Percentile RankBruker Corporation has significant pipeline risk (17/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BRKR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
BRKR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BRKR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BRKR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BRKR Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
BRKR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-06-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-06-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-06-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BRKRBruker Launches new timsMRMS Mass Spectrometry Platform for Unique Ultra-Complex Mixture Applications in the Energy Industry
Bruker has introduced the timsMRMS mass spectrometry platform aimed at addressing unique ultra-complex mixture applications in the energy sector. This launch highlights Bruker's commitment to advancing analytical technology. The new platform is expected to enhance the capabilities of researchers and professionals working with complex mixtures in energy-related fields.
Read more →BRKRBruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics – all to Enable Deeper Insights into Disease Biology
Bruker has announced significant advancements in 4D proteomics, focusing on intact and top-down functional proteoform analysis. These innovations are designed to enhance the understanding of disease biology. The company's developments in hybrid qual/quant 4D metabolomics further support this goal, promising deeper insights for researchers.
Read more →BRKRBruker Reports First Quarter 2026 Financial Results
Bruker Corporation reported its Q1 2026 financial results, revealing revenues of $823.4 million, a 2.7% increase from the previous year. Despite facing challenges such as decreased organic revenue and tariff pressures, the company noted strong bookings in its BSI segment and reaffirmed its FY26 guidance. The introduction of new products at recent conferences has further solidified its market position.
Read more →BRKRBruker Announces Date and Time of First Quarter 2026 Earnings Release and Webcast
Bruker Corporation has announced that it will release its first quarter 2026 financial results on May 6, 2026, before market opening. A conference call and webcast will follow at 8:00 a.m. Eastern Time to discuss these results and business trends. Investors can pre-register for the call to streamline their participation.
Read more →BRKRBruker Expands Industry-Leading MALDI Biotyper® and IR Biotyper® Workflows for Microbial Identification and Outbreak Management
Bruker has announced significant enhancements to its microbial identification and outbreak management solutions at ESCMID Global 2026. Key updates include the introduction of the MBT Easy T® Kit for streamlined workflows, expansion of reference libraries, and the launch of a cloud-based MALDI identification solution. These innovations aim to improve laboratory efficiency and address evolving infectious disease challenges.
Read more →BRKRBruker Spatial Biology Showcases High Fidelity Spatial Data and Integrated Multi-platform Workflows for Unprecedented Multiomic Insights at AACR 2026
Bruker Spatial Biology presented high fidelity spatial data and integrated multi-platform workflows at AACR 2026. The focus was on delivering unprecedented multiomic insights. However, specific details about the findings or technologies were not provided in the article.
Read more →BRKRBruker Launches MyGenius PRO® High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026
Bruker has announced the launch of its MyGenius PRO® system, a high-throughput sample-to-answer molecular diagnostics system, at the ESCMID 2026 event. This system aims to enhance diagnostic capabilities in molecular testing. Further details on its features and applications were not provided in the article.
Read more →BRKRBruker Unveils New NMR Products and Workflow Solutions at ENC 2026
Bruker has introduced new NMR products and workflow solutions at the ENC 2026 event. The announcement highlights the company's commitment to advancing nuclear magnetic resonance technology. Details on the specific products and their applications were not disclosed in the article.
Read more →BRKRBruker Invests in Photothermal AFM-IR to Advance Semiconductor Research
Bruker has made an investment in photothermal AFM-IR technology aimed at enhancing semiconductor research. This move is expected to bolster their capabilities in this field. Further details on the specific applications or expected outcomes of this investment were not provided in the article.
Read more →BRKRBruker Announces Appointment of Thierry Bernard to its Board of Directors
Bruker Corporation has appointed Thierry L. Bernard to its Board of Directors, effective immediately. Bernard, currently the CEO of QIAGEN, has a strong background in the life-science tools and diagnostics industry. His experience is expected to contribute to Bruker's growth in life-science research and diagnostics. Bernard expressed enthusiasm about joining the board and supporting Bruker's mission.
Read more →BRKRBruker Accelerates the Future of Diagnostic and Prognostic Spatial Proteomics with the Launch of CellScape XR
Bruker Corporation has launched CellScape XR, a cutting-edge spatial proteomics platform aimed at enhancing diagnostic and prognostic assay development. This platform addresses key challenges in translational research by providing high-throughput and reproducible spatial proteomics. Collaborations, such as with the University Hospital Schleswig-Holstein, are set to analyze thousands of patient samples, furthering the platform's clinical applications.
Read more →BRKRBruker Expands Collaboration with Noetik to Advance Tissue Foundational Models for Translational and Therapeutic Applications
Bruker Corporation is expanding its collaboration with Noetik Inc. to enhance tissue foundational models for therapeutic applications. This partnership aims to leverage advanced AI models and the CosMx Spatial Molecular Imager to generate extensive datasets for drug discovery. The collaboration seeks to scale data significantly, potentially reaching one billion spatially resolved human cells, which could transform oncology research.
Read more →BRKRBruker Advances Functional Proteomics 2.0 with timsOmniTM Mass Spectrometry Proteoform Analysis for Deeper Insights into Disease Biology
Bruker Corporation has announced advancements to its timsOmni mass spectrometer, enhancing Functional Proteomics 2.0 workflows. New software releases support database-independent PTM discovery and proteoform characterization, enabling deeper insights into disease biology and drug discovery. The integration of AI in peptide sequencing further enhances the accuracy and efficiency of proteomics research.
Read more →BRKRBruker Announces Major Advancements at AGBT to Enable Complete High-Fidelity Spatial Biology Across the Biological Spectrum
Bruker Corporation announced significant advancements in spatial biology at the AGBT 2026 meeting. The company will unveil new products, including the PaintScape platform for 3D genome visualization and the CellScape XR for spatial proteomics. These innovations aim to enhance research capabilities across DNA, RNA, and protein, further integrating multiomics. Additionally, Bruker is collaborating with the University of Glasgow to create a Spatial Biology Center of Excellence.
Read more →BRKRBruker Reports Fourth Quarter and Full Year 2025 Financial Results
Bruker Corporation reported its financial results for Q4 and FY 2025, indicating a slight revenue decrease but an optimistic outlook for FY 2026. The company noted a recovery in biopharma and industrial research markets, leading to better-than-expected Q4 revenues. Management anticipates significant operating margin expansion and double-digit EPS growth in the upcoming fiscal year.
Read more →BRKRChemspeed and SciY Announce Self‑Driving Laboratory Platform Integrating Automation, Analytics and AI Orchestration
Chemspeed Technologies and SciY have launched a Self-Driving Lab (SDL) platform aimed at enhancing R&D and QC workflows through AI orchestration and automation. This platform addresses common laboratory challenges by integrating various systems and providing a unified data environment. The initiative has garnered significant interest from pharmaceutical partners, indicating a demand for scalable, autonomous lab solutions.
Read more →BRKRBruker Announces Quarterly Preferred Stock Dividend
Bruker Corporation has announced a quarterly cash dividend of $3.9844 per share on its 6.375% Mandatory Convertible Preferred Stock. This dividend will be paid on March 2, 2026, to stockholders of record as of February 15, 2026. The announcement underscores Bruker's commitment to returning value to its shareholders.
Read more →BRKRBruker Announces Date and Time of Fourth Quarter 2025 Earnings Release and Webcast
Bruker Corporation has announced the date for its fourth quarter and fiscal year 2025 earnings release, scheduled for February 12, 2026. A conference call and webcast will follow at 8:30 a.m. EST to discuss the results and business trends. Investors can pre-register for the call to streamline their participation.
Read more →BRKRBruker Announces Orders for High-Performance Magnetic Resonance Systems for Materials and Life-Science Research from Leading European Institutions
Bruker Corporation announced substantial orders for high-performance magnetic resonance systems from leading European research institutions. The orders, totaling around $25 million, include advanced NMR systems aimed at enhancing research in drug discovery, battery materials, and disease biology. Revenue recognition for these orders is expected over fiscal 2026 and 2027.
Read more →Competitive Position
How BRKR ranks across every disease it competes inCompetitive Position is a premium feature
See how BRKR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial